The determination of genetic variability of PGE2 receptors, and particularly that of EP3, may be useful to identify patients at risk of nephrosclerosis and/or the detection of patients with this disease that have a higher likelihood of experiencing CV events. This evidence concerns the gene PTGER3 and nephrosclerosis.